Table 1. Prevalence of LTBI During Pregnancy Measured by Tuberculin Skin Test.

Reference	Country	Study period (y)	Participants (n)	US-born (%)*1	Non US-born (%)	Mean age (range)	Interval between testing and reading (h)	Induration cutoff	PPD+ (%)
Cruz [7]	USA	2000	1331	n/s*2	n/s	n/s	n/s	n/s	32%
Metersky [8]	USA	1990–1991	1412	n/s	n/s	n/s	before 48	5 mm	18%
							48–72	10 mm
Magann [9]	USA	n/s	1000	58.5	41.5	25.3 (13–42)	48–72	5–8 mm*3	4%
								8–12 mm *4
								12 mm *5
Jackson[10]	USA	2000	30	47	53	27.5	48–72	10 mm	0%
Meints [11]	USA	2003–2006	382	0	100		n/s	n/s	22%
Medchill [4]	USA	1993–1997	1763	38.2	61.8	n/s	48–72	5 mm	15%
Schwartz [12]	USA	2001–2006	4049	11.1	88.9	27.0 (13.0–46)	n/s	10 mm previously positive	48%
Sackoff [13]	USA	1999–2000	558	0	100	26.0 (22–31)	n/s	10 mm previously positive	37%
Lighter-Fisher [15]	USA	n/s	140	59	41	18.5 (13.5–36.5)	48–72	10 mm	20%
Worjoloh [14]	USA	2009–2010	220	35	65	25 (17–41)	48–72	10 mm*6	21%
								15 mm
Chehab [16]	USA		102	10	90	25.9
Mathad [17]	India	2011–2012	401			n/s	48–72	10 mm	14%
Sheriff [18]	Tanzania	2008	286			25.0 (16–40)	n/s	5 mm *7	30%
								10 mm *8
Sepulveda [19]	Chile	n/a	840			n/s	72	10 mm	51–57%

*¹ When not explicitly detailed, Non-Hispanic Caucasian women were considered US born, whereas women from all other ethnicities were considered non US-born

*² Not specified in article

*³ If suspected of having HIV, or close contact with known case

*⁴ If from endemic area, medically underserved low income populations, residents of long term care facility, migrant workers, homeless

*⁵ If no known risk factors

*⁶ Recent immigrants (<5 years), from high prevalence country, injection drug user, residents or employees of high risk congregate settings

*⁷ HIV positive

*⁸ HIV negative